Recommendations relating to the pre-analytical phase
The pre-analytical phase is in many respects the most important phase of laboratory analysis. Errors in the pre-analytical phase reportedly occur up to ten times as often as in the analytical phase, are often difficult to identify and if unrecognised can seriously compromise patient care. Care and attention to detail when requesting a tumour marker measurement is therefore essential.
Selecting the most appropriate tumour marker Tumour markers may be regarded as surrogate indicators that can increase or decrease a clinician's suspicion that a future clinically important event will or will not occur, and/or that a specific treatment will reduce its likelihood (3) . Their value is in permitting an assessment of risk that should enable therapy to be offered to those patients most likely to benefit, while reducing exposure to toxicities for those who would not benefit. Selection of the most appropriate marker should therefore take heed both of the clinical question -whether risk assessment, screening, diagnosis, prognosis, prediction or monitoring -and of the reliability of the separation in outcomes for marker positive and marker negative patients. Unfortunately there are as yet relatively few welldesigned and validated prospective studies for individual tumour markers. Many of the studies reported in the literature have not been validated thoroughly (i.e. in the same assay, using the same cut-off limits and types of patients), while in others statistical significance (p<0.05) in outcomes of two groups separated by marker results has incorrectly been regarded as evidence of clinical utility, which is not always the case. With these caveats in mind, it is nevertheless possible to make some recommendations about the most appropriate markers in given clinical situations, as summarised in Table 1 for some major cancer sites (3) . [It should be noted that these recommendations apply to requests for tumour marker measurement in routine clinical practice and not necessarily to their use in clinical trials where other considerations may apply.]
Optimising specimen collection
There is no strong evidence of diurnal variation for most markers, so specimens can be taken at any time of day. While the advent of the electronic health record should make it possible to link the ordering process with advice about relevant pre-analytical concerns, pending such developments it is important for both clinical and laboratory staff to be aware of clinical interventions and conditions which may transiently increase tumour markers concentrations. For example, blood for PSA should be taken before any manipulation of the prostate, and blood for CA125 should not be taken during menstruation, which may increase the serum concentration two to three-fold. PSA may also be increased markedly in men with urinary tract infections and prostatitis while CA125 may be mildly elevated in endometriosis and the first two trimesters of pregnancy and markedly raised in any patient with benign ascites. CA19.9 may be significantly increased in patients with cholestasis and patients in this category should be noted on the clinical report. The effect of medication and other treatment should also be considered: 5α-reductase inhibitors cause a median decrease in ƒPSA concentration of approximately 50%. Transient increases in tumour marker concentrations can also occur following chemotherapy. Cannabis may increase serum levels of hCG while smoking may slightly increase apparent CEA levels in some immunoassays. The laboratory should provide clear and readily available advice about the appropriate tube type for each test, so as to ensure that manufacturers' instructions are always followed. Standardised conditions of specimen collection and fixation are crucial for immunohistochemical analyses. Although most tumour markers are reasonably stable, serum or plasma should be separated and stored appropriately as soon as possible. At high ambient temperature the potential influence of transit time on analyte results should be considered. As for other analytes, the majority of preanalytical errors for tumour markers will be simple specimen handling errors -hemolyzed specimens, insufficient specimens, and incorrect specimens -and their occurrence should be minimized by adherence to good laboratory practice. Extra vigilance is required in ensuring that correct tumour marker results are reported, since reporting erroneous results is more likely to cause patients undue alarm than is the case for many other laboratory tests.
Recommendations relating to the analytical phase
In the analytical phase it is essential for satisfactory measurement of any analyte that laboratories ensure that methods used, whether immunoassay or immunohistochemical, are well validated and that their performance is carefully monitored. Implementation of rigorous Internal Quality Control (IQC) procedures and participation in well-designed Proficiency Testing [External Quality Assessment (EQA)] programs should help to ensure that methods are performing according to specification. The NACB has made recommendations for IQC and EQA provision that are generally applicable to all analytes, several factors being especially relevant for tumour marker measurement (3, 4) . Excellent precision and reproducibility (intra-assay variability <5%; inter-assay variability <10%) is essential particularly near critical clinical decision points, for example in screening programs (e.g. when using PSA to select asymptomatic patients for biopsy) or where chemotherapy may be instituted on the basis of a rising tumour marker level in the absence of other scan evidence (e.g. when monitoring testicular cancer patients with AFP and hCG). Longterm assay stability, which can be readily assessed by proficiency testing schemes, should also be demonstrated since tumour markers are often measured for cancer patients over months or years. Such long-term monitoring presents major analytical challenges as patients may be treated in different hospitals using different methods and laboratories may change tumour marker methods during the relevant time period. Data from proficiency testing schemes confirm that there are still significant betweenmethod differences in results, with coefficients of variation in excess of 20% observed for some tumour markers. Poor calibration and differences in the specificity of antibodies used as well as method design all contribute to this variation. A number of international initiatives to address these issues are currently in progress. For the present, considerable care must be taken when changing tumour marker methods or when interpreting cumulated results for individual patients that have been obtained in different methods.
Differences in method design contribute not only to the numerical differences in results observed, but also influence method robustness to clinically relevant interferences. These include cross-reactions with closely related molecules, the high dose hook effect and interference from heterophilic or human antimouse antibodies. Maintaining vigilant awareness of the potential for such interference is very important and requires good understanding of the characteristics of the assays being used. Regular dialogue be-tween laboratory and clinical staff should be actively promoted, since early discussion and investigation of any results that are not in accord with the clinical picture is likely to facilitate early identification of erroneous results caused by interference.
Recommendations relating to the post-analytical phase
In the post-analytical phase, dialogue can be encouraged by provision of brief clinical information by clinicians when requesting tumour marker measurements. It is recommended that laboratory reports for tumour markers include fully cumulated results, an appropriate reference interval and the name of the assay method used, together with an indication of whether any change in marker level is significant and, if appropriate, whether any change of method is likely to have affected interpretation of the trend in marker level (3, 4) . Laboratories should also be actively involved in ongoing audit of the clinical utility of the tumour marker results they provide and of their influence on clinical outcome. Proficiency testing schemes can also contribute by undertaking occasional surveys to compare practice in participating laboratories, highlighting differences in reference intervals, reporting practice and interpretation of clinical results. Such surveys can also provide an indication of how effectively guidelines such as those outlined here are being implemented in routine practice.
